Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0196 • ACR Convergence 2020
Objectively-Measured Obstructive Sleep Apnea Is Frequent Among Individuals with Rheumatoid Arthritis
Stephanie Rush¹, Sarah Morsi², Jose Pinzón Tirado², Laura Trupin², Katie Stone³ and Patricia Katz⁴, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³California Pacific Medical Center Research Institute, San Francisco, CA, ⁴University of California, San Francisco, Novato, CA
Background/Purpose: Despite frequent reports of sleep problems, accurate information on sleep disturbance in rheumatoid arthritis (RA) is not available. Studies using objective measures of sleep…
Abstract Number: 0212 • ACR Convergence 2020
Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks
Roy Fleischmann¹, In-Ho Song², Jeffrey Enejosa³, Eduardo Mysler⁴, Louis Bessette⁵, Patrick Durez⁶, Andrew Östör⁷, Jerzy Swierkot⁸, Yanna Song⁹ and Mark Genovese¹⁰, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Evanston, IL, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, ⁵Laval University, Quebec, Canada, ⁶Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁷Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁸Wroclaw Medical University, Wroclaw, Poland, ⁹AbbVie Inc., North Chicago,, IL, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We report safety/efficacy of upadacitinib (UPA) vs adalimumab (ADA) up to 72 weeks (wks) in patients (pts) with rheumatoid arthritis from the ongoing long-term…
Abstract Number: 0229 • ACR Convergence 2020
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years
Kevin Winthrop¹, Yoshiya Tanaka², Tsutomu Takeuchi³, Alan Kivitz⁴, Franziska Matzkies⁵, Mark Genovese⁵, Deyuan Jiang⁵, Kun Chen⁵, Beatrix Bartok⁵, Angelika Jahreis⁵, Robin Besuyen⁶, Gerd Burmester⁷ and Jacques-Eric Gottenberg⁸, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁴Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos BV, Leiden, Netherlands, ⁷Charité University Hospital Berlin, Berlin, Germany, ⁸Strasbourg University Hospital, Strasbourg, France
Background/Purpose: The oral, selective Janus kinase-1 inhibitor filgotinib (FIL) significantly improved RA signs and symptoms in patients (pts) with MTX-naïve and MTX- and biologic-refractory RA.1–5…
Abstract Number: 0442 • ACR Convergence 2020
Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate
Maria Antonelli¹ and Nora Singer², ¹MHMC/CWRU, Cleveland, OH, ²The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In the initial months of the SARS CoV2/COVID19 pandemic, broad use of off-label therapy with hydroxychloroquine (HCQ) was prescribed to reduce CoV2-related morbidity and…
Abstract Number: 0489 • ACR Convergence 2020
Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jeffrey Sparks¹, Yinzhu Jin¹, Soo-Kyung Cho², Seanna Vine¹, Rishi Desai¹, Tracy J. Doyle³ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations and is more common in older patients. Registry-based RA-ILD…
Abstract Number: 0637 • ACR Convergence 2020
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
Benjamin Naovarat¹, Francis Williams¹ and John Reveille², ¹The University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
Abstract Number: 0754 • ACR Convergence 2020
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
Takayoshi Owada¹, Ayae Tanaka², Hirokuni Hirata¹, Masafumi Arima³, Yasutsugu Fukushima¹ and Kazuhiro Kurasawa³, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Shimotsuga-Gun, Japan, ³Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan
Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
Abstract Number: 0771 • ACR Convergence 2020
Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up
Consuelo Romero-Sanchez¹, Juan Manuel Bello-Gualtero², Juliette De Avila³, Gloria Lafaurie⁴, Philipe Chalem Choueka⁵, Cesar Pacheco Tena⁶, Sebastian Giraldo-Q⁷, Jeimmy Andrea Chaparro-Sanabria⁸, Alejandro Ramos-Casallas³, Lorena Chila-M³ and Wilson Bautista-Molano⁹, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ³Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ⁴Universidad El Bosque, Basic Oral Research Unit – UIBO, School of Dentistry, Bogotá D.C., Colombia, ⁵Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ⁶Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁷Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogota D.C., Colombia, ⁸Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁹University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia
Background/Purpose: In rheumatoid arthritis (RA), autoimmunity towards citrullinated peptides driven the hypothesis, in which periodontal disease (PD) is strongly related to the pathogenesis. Given the…
Abstract Number: 0789 • ACR Convergence 2020
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Xiarepati Tieliwaerdi¹, Nozima Aripova¹, Michael Duryee¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…
Abstract Number: 0822 • ACR Convergence 2020
Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
Janet Pope¹, Stephen Hall², Claire Bombardier³, Edward C Keystone⁴, Boulos Haraoui⁵, Graeme Jones⁶, Latha Naik⁷, Wei David Wu⁸, Dena Ramey⁹, Ricardo Infante¹⁰ and Carol Etzel¹¹, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Emeritus Research, Camberwall, Victoria, Australia, ³Institute for Work and Health, Toronto, ON, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Institute of Montréal, Montreal, Canada, ⁶Menzies Institute for Medical Research, Hobart, Tasmania, Australia, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Merck & Co., Rahway, NJ, ⁹Merck & Co., West Point, PA, ¹⁰Merck & Co., Kenilworth, NJ, ¹¹Corrona, LLC, Southborough, MA
Background/Purpose: COMPANION-B was a prospective real-world observational study designed to provide evidence on the effectiveness of SB4, a biosimilar of ETN compared to ETN originator…
Abstract Number: 0965 • ACR Convergence 2020
Repetitive Inhalant Lipopolysaccharide Exposure in the Setting of Arthritis Induction Potentiates Pro-Fibrotic Inflammatory Lung Disease in Mice
Madison Wolfe¹, Ted Mikuls¹, Geoffrey Thiele¹, Amy Nelson¹, Michael Duryee¹, Rohit Gaurav¹, Bryant England¹, Debra Romberger¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with several lung diseases. Various airborne exposures have been implicated as RA disease risk factors including cigarette smoke and…
Abstract Number: 1003 • ACR Convergence 2020
Long-term Weight Changes and Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort: A Marginal Structural Model Approach
Nathalie Marchand¹, Jeffrey Sparks², Kazuki Yoshida³, Susan Malspeis⁴, Xuehong Zhang⁵, Karen Costenbader⁶, Elizabeth Karlson¹ and Bing Lu⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital and Channing Division of Network Medicine, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Newton, MA
Background/Purpose: The risk of rheumatoid arthritis (RA) has been shown to be elevated among overweight and obese women in several studies, but whether weight gain…
Abstract Number: 1046 • ACR Convergence 2020
Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis
Joe Zhuo¹, Qisu Zhang², Keith Knapp³, Yuexi Wang⁴, Cynthia Gutierrez⁴, Ding He⁴, Lin Xie⁴, Sonie Lama¹ and Gary Craig⁵, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²STATinMED Research (at time of analysis), Ann Arbor, MI, ³Discus Analytics LLC, Spokane, WA, ⁴STATinMED Research, Ann Arbor, MI, ⁵Arthritis Northwest, PLLC, Spokane, WA
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of RA and is associated with increased morbidity and mortality.1 Previous studies have shown variability in…
Abstract Number: 1190 • ACR Convergence 2020
Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA
Elena Myasoedova¹, Cynthia Crowson², Joseph Sexton³, Silvia Rollefstad³ and Anne Grete Semb⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) is associated with 2-fold increase in risk of cardiovascular (CV) disease. Extensive evidence from the general population suggests that control of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.